

### **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) Medicament for the protection against thrombotic diseases, characterized in that it comprises an active principle that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes.
2. (Original) Medicament as claimed in claim 1, characterized in that an antibody induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes.
3. (Currently Amended) Medicament as claimed in claim 1, characterized in that it comprises the monoclonal antibody JAQ1 deposited under Accession Number DSM ACC 2487.
4. (Original) Medicament as claimed in claims 1 and 2, characterized in that it contains an antibody against the thrombocyte collagen receptor GPVI.
5. (Currently Amended) Medicament as claimed in claims 1 to 3, characterized in that it contains ~~the humanised~~ a humanized monoclonal antibody JAQ1.
6. (Currently Amended) A diagnostic agent for the determination of the expression rate of the collagen receptor GPVI, characterized in that it contains a ~~labelled~~ labeled monoclonal or polyclonal antibody directed against the GPVI epitope, ~~preferably as defined by JAQ1~~.
7. (Withdrawn) A method for the determination of the expression rate of the collagen receptor GPVI in blood characterized in that

- a) a sample of the blood of the patient is incubated with a solid carrier on which the antibody JAQ1 is fixed, washing the carrier, incubating it with a second labelled antibody JAQ1, washing the carrier again and measuring the signal of the second labelled antibody; or
- b) a sample of the blood of the patient is fixed on a solid carrier and thereafter treated with the labelled antibody JAQ1 alone or in mixture with the unlabeled antibody JAQ1 and subsequently the labelled antibody is detected; or
- c) the monoclonal antibody JAQ1 is fixed on a solid carrier and is thereafter contacted with the blood sample, which is to be tested, together with the labelled antibody JAQ1, washing the carrier and measuring the signal of the labelled antibody.

8. (Withdrawn) A method is claimed in claim 6, characterized in that it is performed using a fluorescence-labelled monoclonal JAQ1 antibody in a flow-cytometer.

9. (Currently Amended) A hybridoma cell line for the production of the monoclonal antibody JAQ1 ~~which cell line carries the deposition number DSM ACC 2487~~ deposited under Accession Number DSM ACC 2487.

10. (Currently Amended) A monoclonal ~~Monoclonal~~ antibody, characterized in that it binds to the same or a similar epitop epitope of the collagen receptor for thrombocytes as the monoclonal antibody JAQ1 deposited under Accession Number DSM ACC 2487.

11. (Currently Amended) A method of preparing a medicament against thrombotic diseases, wherein Use of the an active principle that induces an irreversible

inactivation or degradation of a collagen receptor on thrombocytes is combined with a pharmaceutically acceptable carrier ~~for the preparation of a medicament against thrombotic diseases.~~

12. (Currently Amended) The method of ~~Use as claimed in~~ claim 11, wherein the active principle is a monoclonal antibody.

13. (Currently Amended) The method of ~~Use as claimed in~~ claims 11 and 12, wherein the active principle is the monoclonal antibody JAQ1 deposited under Accession Number DSM ACC 2487.